Module 3
Global Regulatory Frameworks: EU, FDA and WHO
Course Overview
This course establishes the essential regulatory intelligence every pharmaceutical employee needs to understand why the global regulatory system exists, how it is structured, how it is enforced, and how compliance with it protects patients, preserves market access and sustains the organisation’s licence to operate.
Regulatory frameworks are not the exclusive territory of regulatory affairs professionals. Every function that designs, manufactures, tests, stores, distributes, documents, imports, exports or commercialises a medicinal product operates within a regulatory obligation. Production teams follow manufacturing standards set by regulators. QA professionals apply quality systems shaped by regulatory expectations. Engineering teams qualify equipment against regulatory requirements. Supply chain functions manage products whose approval status, storage conditions and distribution channels are all defined by regulatory decisions. Senior leaders make investment and governance decisions that affect the organisation’s regulatory standing. When any of these functions misunderstands the regulatory framework, the consequences extend far beyond a single department.
This course builds a rigorous, operationally grounded understanding of the two most influential regulatory frameworks in global pharmaceutical manufacturing – the EU GMP framework and the US FDA framework – while situating both within the broader international regulatory landscape. Learners will understand how the EU and FDA systems are constructed, how they interact with each other, how international harmonisation bodies shape national regulation, and how regulators think, prioritise and make enforcement decisions.
The course also addresses the practical reality of operating in a multi-market regulatory environment: how mutual recognition agreements affect inspection reliance, how post-Brexit regulatory divergence has created distinct obligations for MHRA, EMA and EU Competent Authority-facing operations, how WHO, PIC/S, Health Canada, TGA and other authorities relate to the frameworks learners encounter daily, and how regulatory change is identified, tracked and translated into operational compliance.
Throughout, the course anchors regulatory knowledge to patient safety outcomes, licence accountability and inspection readiness. Regulators do not write guidance for the satisfaction of doing paperwork. They write it because failures – adulterated products, falsified records, inadequate manufacturing controls, unreliable suppliers and insufficient oversight – have harmed patients. Understanding the regulatory framework means understanding what those failures looked like and why the current expectations are what they are.
Learning Outcomes
By the end of this course, learners will be able to:
- Explain why pharmaceutical regulatory frameworks exist and how they connect to patient safety, product quality, public trust, licence accountability and market
- Describe the structure of the EU GMP framework, including EU GMP Parts I, II and III, the Annex system, the role of the European Medicines Agency, EU Competent Authorities and the relationship between manufacturing authorisation and GMP compliance.
- Describe the structure of the FDA regulatory framework, including 21 CFR Parts 210 and 211, how FDA oversight is organised across CDER and CBER, and how FDA inspection programmes are structured and prioritised.
- Explain how ICH guidelines – including the Q, S and E series – are developed, adopted into regional regulation and applied in pharmaceutical operations.
- Describe the role of PIC/S in harmonising GMP standards and inspection practices across member authorities, and explain how mutual recognition agreements affect inspection reliance and regulatory trust.
- Describe the WHO regulatory framework including the WHO TRS series for GMP, the WHO Prequalification Programme, the role of WHO standards in the global regulatory system and how WHO-aligned regulatory authorities apply these standards in countries without independent stringent regulatory authority status.
- Explain the relationship between WHO standards, ICH guidelines, EU GMP and FDA expectations, and how organisations supplying products to multiple markets including WHO PQ-relevant markets navigate the framework intersections.
- Explain the current regulatory relationship between the MHRA and the EMA following the UK’s exit from the EU, and identify key areas of regulatory divergence and alignment.
- Recognise how different departments – including QA, production, regulatory affairs, engineering, supply chain, QC, procurement, commercial operations and senior leadership – create or carry regulatory obligations and affect the organisation’s regulatory standing.
- Identify the stages of an FDA inspection, from pre-inspection preparation through conduct, classification and follow-up, and explain how Form 483 observations and Warning Letters are generated and managed.
- Explain how EU GMP inspections are conducted, how non-compliance statements are issued and what the consequences of a critical finding or inspection failure are for licence status and supply continuity.
- Assess how regulatory change – new guidance, revised Annexes, updated ICH guidelines, post-approval commitments and policy shifts – should be tracked, evaluated for operational impact and implemented through the local Pharmaceutical Quality System.
- Recognise situations that require escalation, including potential regulatory commitments not reflected in site practice, unassessed regulatory changes, inspection observations with unresolved root cause, and cross-market compliance gaps.
3.5Hrs of instructor led learning
Usable documents and templates
Real work examples and exercises
Course Content
Regulatory failure is expensive in a way that most business risks are not. An FDA Warning Letter is public, permanent and commercially damaging. An EU GMP non-compliance statement can suspend a manufacturing authorisation and halt supply. An MHRA inspection finding can trigger a product recall, a licence variation or an import ban. A mutual recognition breakdown can block a product from markets served by partner authorities. These are not theoretical outcomes. They are the routine consequences of inadequate regulatory understanding applied at operational level.
Many organisations discover this the hard way. A production team runs a process outside its registered parameters because nobody connected the SOP to the regulatory submission. A quality team approves a change without recognising its variation classification. A supply chain function uses an unapproved manufacturer because the regulatory approval status was not confirmed before the purchase order was placed. An engineering team modifies validated equipment without understanding the post-approval change implications. None of these failures requires bad intent. They require only a workforce that understands operational procedures without understanding the regulatory framework those procedures are designed to satisfy.
Regulators are also aware of this pattern. FDA inspectors look not only for whether a company follows its SOPs, but whether it understands why those SOPs exist, whether its quality system reflects regulatory commitments, and whether it monitors and responds to regulatory change proactively. EU Competent Authority inspectors assess whether quality culture, management oversight and cross-functional accountability are genuine rather than performed. An organisation that presents a well-maintained quality system without evidence that its people understand the regulatory obligations behind it is unlikely to inspire lasting regulatory confidence.
This course is also essential because the regulatory landscape is not static. The Annex 1 revision of 2022 represented the most significant overhaul of sterile manufacturing expectations in a generation. ICH Q2(R2) and Q14 have updated analytical validation and development expectations. FDA continues to develop risk-based inspection models and guidance on data integrity, computerised systems and advanced manufacturing. MHRA is establishing its post-Brexit regulatory identity. Organisations that treat regulatory knowledge as something acquired once and never revisited are building compliance on foundations that have already shifted.
The global regulatory landscape
The course opens by mapping the international pharmaceutical regulatory environment. Learners will understand how FDA, EMA, MHRA, WHO, Health Canada, TGA, PMDA and other major authorities are structured, what they regulate, and how their inspection and approval activities affect pharmaceutical operations. The course explains the difference between a national Competent Authority, a supranational regulatory agency and an international harmonisation body, because confusing these three categories is a reliable source of regulatory misunderstanding.
The role of ICH is addressed in full. Learners will understand how the International Council for Harmonisation develops technical guidelines, how the Q, S and E series guidelines are structured, and how adopted ICH guidelines become incorporated into regional regulation. This includes practical guidance on which ICH guidelines are most operationally relevant – Q8 through Q14 in particular – and how they interact with site quality systems, validation programmes, analytical development, risk management and regulatory submissions.
PIC/S membership and its significance are explained clearly. Learners will understand how PIC/S harmonises GMP standards and inspection practices across participating authorities, why PIC/S membership increases regulatory trust between member countries, and how inspection reports and GMP certification may be relied upon by partner authorities under mutual recognition or information-sharing arrangements.
The WHO regulatory framework and WHO Prequalification
A dedicated section addresses the World Health Organization’s regulatory framework, which is widely under-appreciated outside the global health and tendered product supply context. Learners will understand the WHO Technical Report Series (TRS) GMP standards, the relationship between WHO GMP and the wider ICH/EU/FDA framework, and the operational reality of WHO GMP inspection where it applies.
The WHO Prequalification Programme is addressed in operational depth. Learners will understand the categories of product covered by WHO PQ (medicines, vaccines, in vitro diagnostics, vector control products and biotherapeutics), the dossier and inspection requirements for WHO PQ status, the strategic importance of PQ for organisations supplying global health markets and the relationship between WHO PQ inspection and Stringent Regulatory Authority inspection.
The course explains how WHO standards function in countries that have adopted WHO standards as their national regulatory framework, how WHO Listed Authority status changes the regulatory landscape for participating authorities, and how multi-market regulatory strategies should accommodate WHO requirements alongside EU, FDA and other national frameworks. The course addresses the practical reality that WHO PQ inspection is distinct in approach and emphasis from EU and FDA inspection, and that organisations seeking PQ status need to prepare for WHO-specific inspection considerations.
The EU GMP framework
The EU GMP framework is addressed in depth. Learners will understand the legal basis for EU pharmaceutical regulation, the role of the European Medicines Agency and national Competent Authorities, and how marketing authorisation, manufacturing authorisation, wholesale distribution authorisation and import authorisation each create distinct regulatory obligations.
The structure of EU GMP is covered in detail: Part I for finished medicinal products, Part II for
active pharmaceutical ingredients, Part III for supporting documents including ICH guidelines adopted into EU GMP, and the Annex system which applies supplementary requirements for specific product types, manufacturing activities and quality system elements. Learners will understand the status of key Annexes including the revised Annex 1 (2022), Annex 11 on computerised systems, Annex 13 on clinical trial manufacture, Annex 15 on qualification and validation, Annex 16 on batch certification, and Annex 17 on parametric release.
The Qualified Person obligation is addressed in the context of the regulatory framework. Learners who are not QPs will gain a practical understanding of why the QP role exists, what batch certification means, and why the QP’s decisions connect directly to the regulatory standing of the product and the manufacturing site.
EU GMP inspections are explained from the perspective of how they are planned, conducted and concluded. This includes routine inspections, for-cause inspections, pre-approval inspections and inspections conducted under mutual recognition or reliance arrangements. The course explains how inspection outcomes are classified, what a critical deficiency means for a manufacturing site, and how non-compliance statements and suspension of manufacturing authorisation affect supply chains, product availability and patient access.
The FDA regulatory framework
The FDA framework is addressed with equivalent depth. Learners will understand the structure of FDA regulation under Title 21 of the Code of Federal Regulations, with particular focus on Parts 210 and 211 for finished pharmaceutical products, and how FDA’s centres – CDER, CBER and OPQ – organise their regulatory oversight.
FDA’s inspection programme is explained in practical terms. This includes how FDA selects sites for inspection using a risk-based model that considers inspection history, product risk, time since last inspection, import status and post-approval commitments. The difference between a domestic inspection and a foreign inspection, and between a surveillance inspection and a pre-approval inspection, is explained with operational context.
The FDA inspection process itself is covered in full. Learners will understand what happens before an inspection, how FDA investigators conduct walkthroughs, interviews and record reviews, how they document observations on Form 483, and how the establishment inspection report is prepared. The course explains how Form 483 observations should be responded to, what the consequences of an inadequate response are, and how Warning Letters are issued, disclosed publicly and managed through corrective commitments.
MHRA and Post-Brexit Regulatory Divergence
The UK regulatory environment is addressed with appropriate depth for a post-Brexit world. Learners will understand how the MHRA operates as an independent regulatory authority following the UK’s exit from the EU, how UK GMP expectations compare with EU GMP, and where meaningful divergence has emerged or is anticipated. The course also explains how the Northern Ireland Protocol and the Windsor Framework affect regulatory arrangements for products moving between Great Britain, Northern Ireland and the EU.
Mutual Recognition Agreements and Regulatory Reliance
Mutual recognition agreements between major regulatory authorities – including the EU-FDA MRA and related bilateral arrangements – are explained in terms of their practical significance. Learners will understand what an MRA means for GMP inspection reliance, how it affects the inspection frequency and source authority for manufacturing sites operating in MRA-covered territories, and what conditions can trigger suspension or non-application of an MRA arrangement.
Regulatory Change Management
The course addresses how regulatory change should be managed operationally. Learners will understand how to monitor changes to guidance documents, revised Annexes, new ICH guidelines, updated agency expectations and post-approval commitments. The course explains how regulatory change should be assessed for operational impact, translated into change control activities, communicated across the organisation and implemented through the local Pharmaceutical Quality System. This section also addresses escalation behaviour: when an identified regulatory change requires immediate action, who should be informed, and why the instinct to monitor something without acting is a common source of compliance gap.
Cross-Functional Regulatory Accountability
A dedicated section examines how different departments carry and create regulatory obligations. Production teams operating outside registered parameters create regulatory non-compliance regardless of whether the product passes testing. QC laboratories using unregistered methods or unqualified equipment put regulatory submissions at risk. Engineering teams implementing changes without assessing post-approval impact may inadvertently breach manufacturing authorisation conditions. Procurement functions approving unapproved suppliers or materials may introduce ingredients or components not authorised for use in licensed products. Commercial functions entering new markets without regulatory approval create enforcement exposure. Senior leaders making resource decisions that compromise the quality system affect the organisation’s ability to meet its regulatory commitments.
The course uses scenario-based examples across these functions to show how regulatory accountability is genuinely distributed across the organisation – not delegated entirely to regulatory affairs.
- Regulatory Affairs professionals at all levels, from associates building their regulatory foundation to managers and directors responsible for multi-market compliance strategies.
- QA professionals with responsibilities that involve interpreting regulatory requirements, managing inspection readiness, supporting regulatory submissions or overseeing compliance with EU GMP, FDA and MHRA expectations.
- Qualified Persons and Deputy QPs who need a comprehensive understanding of the regulatory framework within which batch certification decisions are made.
- QPs-in-training and those pursuing the QP knowledge base who need to understand global regulatory frameworks as part of their qualifying experience.
- Site Quality Directors, Head of Quality and VP Quality roles accountable for regulatory standing across single or multiple sites.
- Manufacturing, operations and production leadership whose activities are subject to regulatory oversight and whose decisions affect regulatory compliance.
- Engineering, validation and technical operations personnel whose qualification and validation activities must align with regulatory expectations and post-approval commitments.
- Supply chain, import/export and logistics professionals managing products across regulatory jurisdictions.
- Procurement and supplier quality teams whose decisions about approved suppliers, materials and services carry regulatory significance.
- Commercial, business development and market access professionals who need to understand how regulatory decisions affect product availability, supply timelines and market entry.
- Senior leaders, executive teams and board-level governance functions who carry organisational accountability for regulatory compliance.
- Employees, contractors and third parties at any level who need to understand the regulatory framework within which their role operates.
You will gain a rigorous and operationally relevant understanding of the regulatory frameworks that govern the pharmaceutical industry. You will be able to read and interpret EU GMP requirements, FDA regulations and ICH guidelines with genuine comprehension rather than surface familiarity. You will understand how inspectors think, what they look for and what triggers enforcement action. You will be able to contribute to regulatory discussions, inspection preparation activities and compliance assessments with greater confidence and credibility.
For those in regulatory affairs, quality, manufacturing, engineering or supply chain, this course provides the regulatory intelligence needed to make better decisions in daily work. For those in leadership, commercial or support functions, it provides the context needed to understand why regulatory compliance is not a cost to be managed but a condition of continuing to operate.
Organisations benefit from a workforce that understands the regulatory framework as a shared obligation, not a specialist concern. This reduces the risk of inadvertent regulatory non-compliance arising from functional siloes, improves cross-functional assessment of regulatory change impact, strengthens inspection readiness across all departments, and supports more coherent responses to regulatory queries, observations and enforcement actions.
When people understand what regulators actually look for and why, inspection preparation becomes a genuine quality activity rather than a fire drill. When regulatory change is understood across the organisation, implementation is faster and more reliable. When everyone from the production floor to the boardroom understands that regulatory compliance and patient protection are two descriptions of the same obligation, the quality culture becomes self-reinforcing rather than dependent on periodic reminders from QA.
Organisations that treat regulatory knowledge as specialist knowledge are also organisations that are regularly surprised by inspections. That is not a comfortable position, and it is entirely preventable.
- Comprehensive expert video content covering EU GMP, FDA, MHRA, ICH, PIC/S and the global regulatory landscape.
- Real-world case studies from pharmaceutical manufacturing, regulatory affairs, supply chain, import/export and multi-market compliance environments.
- Practical examples of regulatory framework application across production, QA, QC, engineering, supply chain, procurement, commercial operations and senior
- Cross-functional scenarios showing how different departments create, carry and affect regulatory obligations.
- Inspection-readiness examples covering FDA inspection conduct, Form 483 responses, Warning Letter management, EU GMP inspection outcomes and non-compliance consequences.
- Exercises on regulatory change identification, impact assessment, escalation behaviour and local PQS application.
- Practical examples of mutual recognition arrangements, post-Brexit regulatory divergence and multi-market compliance decision-making.
- Multi-choice assessment.
- Certificate of completion upon passing the
Course Details
Instructor:
Farah Nadeem
Level:
Core Principles
Duration:
3.5 Hours
Type:
On Demand
Launch Yourself Into The Future.
Join Academy Pharmaceutical Excellence to gain industry-leading knowledge and skills through our comprehensive courses designed for aspiring professionals.